AMCR Forensic analysis

Trading Setup & Entry Strategy

• >Entry Zone: $35.50 - $36.20. Scale in with 40% position at $36.15 (near lower Bollinger Band support) and 60% if price taps $35.50 (major psychological support/swing low zone).
• >Stop Loss: $34.40 (Hard stop). Rationale: A breach of this level invalidates the recovery thesis and confirms a breakdown from the $36.00 range.
• >Take Profit: $38.80 (Target 1, 10-day SMA), $40.50 (Target 2, resistance zone).
• >Risk/Reward: ~1:2.8 (Targeting $3.80 upside vs $1.60 downside).
• >Maximum Hold Time: 2 weeks.

Financial Health & Forensic Flags

• >Balance Sheet: $15.85B in total debt, up significantly following the $10.4B acquisition of Berry Global. Debt-to-EBITDA remains a critical watchpoint.
• [WARN]Earnings Quality: Red Flag: Recorded out-of-period adjustments in Q2 FY26 regarding inventory discrepancies in Asia operations. While management claims materiality is low, combined with recent integration costs, it suggests potential weaknesses in international reporting controls.
• >Operational Efficiency: The Berry Plan integration is ongoing, targeting $530M in synergies by FY28, but current costs are weighing on margins.

Valuation & Technical Reconciliation

• >Valuation: Trading at ~12x forward earnings. Valuation is supportive, but market sentiment is currently dominated by concerns over 'stretch' earnings guidance and macroeconomic headwinds.
• >Technical Status: BEARISH_DOWNTREND. Price sits below all major SMAs (5, 10, 50, 200). The RSI of 38.02 indicates it is approaching oversold, suggesting a potential short-term mean reversion bounce.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Position Sizing: 3% of portfolio. High volatility environment requires smaller sizing.
• >Scaling Strategy: Enter 40% now, add 60% on a retest of $35.50. Exit 50% at $38.50, remainder at $40.00.
• >Catalyst: Market is currently digesting downgraded EPS/FCF guidance; focus is on stabilization of the core business and success of the strategic portfolio review (divestitures).

One-Liner Thesis: AMCR is currently a value-driven "hope trade" testing technical floor support; prioritize liquidity and tight stops as integration risks and macro-volatility keep institutional conviction low.